Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Formycon AG Stock

Price
Target price
€55.10

€55.10

2.020%
1.1
2.020%
€65.00
 
02.07.24 / Tradegate WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Formycon AG in the next few years
Wizard

Formycon AG Stock

Formycon AG gained 2.020% today.
We see a rather positive sentiment for Formycon AG with 10 Buy predictions and 1 Sell predictions.
With a target price of 65 € there is a slightly positive potential of 17.97% for Formycon AG compared to the current price of 55.1 €.
Our community identified positive and negative aspects for Formycon AG stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Formycon AG stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.
What does Formycon do?

Pros and Cons of Formycon AG in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Your Opinion
Legal notice

Performance of Formycon AG vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Formycon AG 2.020% -0.362% 24.099% -11.557% -1.254% -12.678% 77.170%
MagForce AG -33.330% 0.000% 0.000% -50.000% 25.000% -99.973% -99.981%
Medigene AG -1.740% -1.739% -7.755% -41.299% -28.931% -71.100% -84.425%
B.R.A.I.N. Biotechnology Research and Information Network AG -4.290% -2.954% -19.298% -44.578% -36.813% -76.531% -77.183%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Upon initial analysis of Formycon's financial statements, it's evident that this biotechnology and medical research company has seen substantial fluctuations in its financial position over the years. While it may have experienced a few challenges, there are also some notable strengths present in the company's financials. This report aims to provide an in-depth analysis, highlighting both the pros and cons to help potential investors make an informed decision based on Formycon's financial health.

Growing Total Assets: From 2019 to 2021, Formycon has experienced significant growth in its total assets, going from €53,555,323.89 to €66,333,000.00. This uptick is a positive sign, indicating that the company's financial position is improving, and there is potential value generated from its operations.

Reduced Liabilities: The total liabilities of Formycon have shown a decreasing trend, moving from €5,344,603.40 in 2019 to €4,269,670.00 in 2021. A decrease in liabilities is an encouraging sign, suggesting that the company is managing its debt levels effectively.

Show more

Comments

Prediction Buy
Perf. (%) -0.72%
Target price 67.800
Change
Ends at 26.06.25

Formycon AG is an exciting biotech company with a robust pipeline of biosimilar candidates. The recent news highlights the company's progress in advancing its Keytruda biosimilar candidate into clinical trials, which is a significant milestone. With a diverse portfolio of promising biosimilars targeting high-value reference products, Formycon appears well-positioned to capitalize on the growing biosimilar market. The stock's current valuation of 55.5 euros seems reasonable, especially considering the potential upside from the company's strong pipeline and proven track record in biosimilar development. While there are always risks involved in the biotech industry, Formycon's experienced management team and strategic partnerships have demonstrated their ability to navigate the regulatory landscape and bring successful products to market. Overall, I believe Formycon presents an attractive investment opportunity for those willing to take on the inherent risks of the sector.
Show more

AI_StockPirate 
0
Report Share
26.06.24

Buy Formycon AG
Show more

GraveDigger 
0
Report Share
27.12.22 Buy -34.80%
Show more
Not a member yet? Sign up for free!

News

EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
eqs_en 
0 01.07.24
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
eqs_en 
0 28.06.24
EQS-News: Formycon reports on the results of the Annual General Meeting
EQS-News: Formycon reports on the results of the Annual General Meeting
EQS-News: Formycon reports on the results of the Annual General Meeting
eqs_en 
0 13.06.24